Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05966038 · ClinicalTrials.gov registry record

ALS/MND Natural History Study Data Repository

A clinical trial of ALS and PLS, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
5,000
Enrollment target
16
Study locations

NCT05966038 is a study of ALS and PLS that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 5,000 participants, above the 774-participant average among 19 other ALS trials with a reported enrollment target (546% higher). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05966038, a study of ALS and PLS, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
5,000 participants
Enrollment target
16
Study locations

Study Summary

This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study. The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The information is captured in NeuroBANK, a patient-centric clinical research platform. The Sites have an option to choose to collect data into 20+ additional forms capturing biomarkers and outcome measures. Captured data after its curation are anonymized (all personal identifiers and dates are being removed), and the anonymized dataset is shared with medical researchers via a non-exclusive revocable license. Funding Source - Biogen, Inc.; Mitsubishi Tanabe Pharma America; FDA OOPD.

Study Locations (16)

Other

  • Hadassah Medical Organization - Jerusalem
  • Tel Aviv Medical Center - Tel Aviv
  • Centro Clinico NEMO Milano - Milan
  • Istituti Clinici Scientifici Maugeri SpA - Milan

California

  • Loma Linda University Health - Loma Linda
  • Kaiser Permanente - Los Angeles

Pennsylvania

  • Temple University Lewis Katz School of Medicine - Philadelphia
  • University of Pittsburgh - Pittsburgh

Florida

  • University of Florida - Gainesville

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Lahey Clinic - Burlington

Michigan

  • Henry Ford Health System - Detroit

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2015-04-01
Est. Completion 2030-12-31

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05966038

The ClinicalTrials.gov registry entry for NCT05966038 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 774-participant average among 19 other ALS trials with a reported enrollment target (546% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with ALS appearing as the primary indexed condition, and to 0 interventions.

NCT05966038 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05966038 about?

NCT05966038 is a clinical study titled "ALS/MND Natural History Study Data Repository". This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND). All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study. The Sites collect so-called ...

What is the current status of trial NCT05966038?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2015-04-01. Estimated completion is 2030-12-31.

What conditions does trial NCT05966038 study?

This clinical trial studies the following conditions: ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy.

Who is sponsoring clinical trial NCT05966038?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05966038 being conducted?

This trial has 16 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ALS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.